Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells

被引:21
作者
Younesi, Vahid [1 ]
Nejatollahi, Foroogh [1 ,2 ]
机构
[1] Shiraz Univ Med Sci, Dept Immunol, Recombinant Antibody Lab, Shiraz, Iran
[2] Shiraz Univ Med Sci, Shiraz HIV AIDS Res Ctr, Shiraz, Iran
关键词
Targeted therapy; Interleukin-25; Breast cancer; Anti-IL25 receptor scFv; INTERLEUKIN-17; FAMILY; PHAGE DISPLAY; IL-17; EXPRESSION; CYTOKINES;
D O I
10.1016/j.intimp.2014.10.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Overexpression of IL-25 receptor (1-25R) on the surface of malignant, but not normal, breast epithelial cells contributes to tumorigenic potential of breast cancer cells. IL-25/IL-25R binding results in specific apoptosis in breast cancer cells. In this study, the inhibitory effects of anti-IL-25R scFv antibodies on three breast cancer cells were evaluated. Panning process was performed on a phage library to isolate scFvs against two specific epitopes of IL25R. The reactivities of scFvs were assessed using phage ELISA. Cell binding capacity of the selected scFvs on breast cancer cells was analyzed using flow cytometry. Anti-proliferative and apoptotic effects of scFvs were evaluated by MTT, Annexin V/PI and quantitative caspase 3 activity assays. Two scFvs with frequencies of 47% and 68% were selected against peptides I and II, respectively. Phage ELISA demonstrated the specific reactions of the scFvs against the corresponding peptides. The scFvs against peptides I and II bound to 14% and 21% of MDA-231, 28% and 32% of MCF7, and 21% and 30% of SKBR3 cells, respectively. Treatment of the breast cancer cells with IL-25 and two anti-IL-25R scFvs resulted in significant inhibition of the cell growth in these cell compared to that in IL-25R negative Rail cells. The results also demonstrated 66% and 70% apoptosis cell death and 15.5 and 17 fold increases in caspase-3 activity in SKBR3 cells induced by scFvs land II, respectively. Our findings suggest the targeting of IL-25R by scFvs as a new effective strategy in breast cancer immunotherapy. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:624 / 632
页数:9
相关论文
共 32 条
[1]   Antibodies in Single-Chain Format Against Tumour-Associated Antigens: Present and Future Applications [J].
Accardi, L. ;
Di Bonito, P. .
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (17) :1730-1755
[2]  
Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1
[3]  
Albrecht H, 2007, Q J NUCL MED MOL IM, V51, P304
[4]   IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo [J].
Benatar, Tania ;
Cao, Ming Y. ;
Lee, Yoon ;
Lightfoot, Jeff ;
Feng, Ningping ;
Gu, Xiaoping ;
Lee, Vivian ;
Jin, Hongnan ;
Wang, Ming ;
Wright, Jim A. ;
Young, Aiping H. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (06) :805-817
[5]   Cytokines in cancer pathogenesis and cancer therapy [J].
Dranoff, G .
NATURE REVIEWS CANCER, 2004, 4 (01) :11-22
[6]   Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells [J].
Furuta, S ;
Jiang, XZ ;
Gu, BN ;
Cheng, E ;
Chen, PL ;
Lee, WH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (26) :9176-9181
[7]   IL-25 Causes Apoptosis of IL-25R-Expressing Breast Cancer Cells Without Toxicity to Nonmalignant Cells [J].
Furuta, Saori ;
Jeng, Yung-Ming ;
Zhou, Longen ;
Huang, Lan ;
Kuhn, Irene ;
Bissell, Mina J. ;
Lee, Wen-Hwa .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (78)
[8]   Structure and signalling in the IL-17 receptor family (vol 9, pg 556, 2009) [J].
Gaffen, Sarah L. .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (08) :556-567
[9]   Development of an EGFRvIII specific recombinant antibody [J].
Gupta, Puja ;
Han, Shuang-Yin ;
Holgado-Madruga, Marina ;
Mitra, Siddhartha S. ;
Li, Gordon ;
Nitta, Ryan T. ;
Wong, Albert J. .
BMC BIOTECHNOLOGY, 2010, 10
[10]   Single-chain antibodies as diagnostic tools and therapeutic agents [J].
Hagemeyer, Christoph E. ;
von zur Muhlen, Constantin ;
von Elverfeldt, Dominik ;
Peter, Karlheinz .
THROMBOSIS AND HAEMOSTASIS, 2009, 101 (06) :1012-1019